American journal of nuclear medicine and molecular imaging最新文献

{"title":"Modeling contrast-to-noise ratio from list mode reconstructions of ⁶⁸Ga DOTATATE PET/CT: predicting detectability of hepatic metastases in shorter acquisition PET reconstructions.","authors":"Michael Silosky,&nbsp;Fuyong Xing,&nbsp;John Wehrend,&nbsp;Daniel V Litwiller,&nbsp;Scott D Metzler,&nbsp;Bennett B Chin","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>Deep learning (DL) algorithms have shown promise in identifying and quantifying lesions in PET/CT. However, the accuracy and generalizability of these algorithms relies on large, diverse datasets which are time and labor intensive to curate. Modern PET/CT scanners may acquire data in list mode, allowing for multiple reconstructions of the same datasets with different parameters and imaging times. These reconstructions may provide a wide range of image characteristics to increase the size and diversity of datasets. Training algorithms with shorter imaging times and higher noise properties requires that lesions remain detectable. The purpose of this study is to model and predict the contrast-to-noise ratio (CNR) for shorter imaging times based on CNR from longer duration, lower noise images for ⁶⁸Ga DOTATATE PET hepatic lesions and identify a threshold above which lesions remain detectable.</p><p><strong>Methods: </strong>⁶⁸Ga DOTATATE subjects (n=20) with hepatic lesions were divided into two subgroups. The \"Model\" group (n=4 subjects; n=9 lesions; n=36 datapoints) was used to identify the relationship between CNR and imaging time. The \"Test\" group (n=16 subjects; n=44 lesions; n=176 datapoints) was used to evaluate the prediction provided by the model.</p><p><strong>Results: </strong>CNR plotted as a function of imaging time for a subset of identified subjects was very well fit with a quadratic model. For the remaining subjects, the measured CNR showed a very high linear correlation with the predicted CNR for these lesions (R² > 0.97) for all imaging durations. From the model, a threshold CNR=6.9 at 5-minutes predicted CNR > 5 at 2-minutes. Visual inspection of lesions in 2-minute images with CNR above the threshold in 5-minute images were assessed and rated as a 4 or 5 (probably positive or definitely positive) confirming 100% lesion detectability on the shorter 2-minute PET images.</p><p><strong>Conclusions: </strong>CNR for shorter DOTATATE PET imaging times may be accurately predicted using list mode reconstructions of longer acquisitions. A threshold CNR may be applied to longer duration images to ensure lesion detectability of shorter duration reconstructions. This method can aid in the selection of lesions to include in novel data augmentation techniques for deep learning.</p>","PeriodicalId":7572,"journal":{"name":"American journal of nuclear medicine and molecular imaging","volume":"13 1","pages":"33-42"},"PeriodicalIF":2.5,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10009466/pdf/ajnmmi0013-0033.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9116673","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Co-injection of anti-HER2 antibody Trastuzumab does not increase efficacy of [¹⁷⁷Lu]Lu-PSMA-617 therapy in an animal model of prostate cancer.","authors":"Ayman Abouzayed,&nbsp;Wahed Zedan,&nbsp;Mohamed Altai,&nbsp;Joanna Strand,&nbsp;Anders Örbom","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>One novel option for treating metastatic castration resistant prostate cancer is radionuclide therapy targeting prostate-specific membrane antigen (PSMA), e.g. [¹⁷⁷Lu]Lu-PSMA-617. Overexpression of HER2 has been found in 80% of metastatic cases of prostate cancer. Previous research showed that HER2 is elevated post irradiation in PC-3 prostate cancer cells. Co-treating with anti-HER2 antibody Trastuzumab gave less proliferation of irradiated tumor cells in vitro, and when using radionuclide therapy, also in vivo. The aim of this study is to determine whether the same holds true in PSMA-expressing PC-3 PIP cells using [¹⁷⁷Lu]Lu-PSMA-617 radionuclide therapy. PC-3 PIP and 22Rv1 prostate cancer cells were tested in vitro, treated with 6 Gy of x-rays with or without Trastuzumab incubation. We measured uptake of HER2-targeting affibody [⁶⁸Ga]Ga-ABY-025 and cell survival, e.g. using the WST-1 assay. Three groups (n=10 each) of male nude Balb/c mice were inoculated with PC-3 PIP xenograft tumors and treated with just [¹⁷⁷Lu]Lu-PSMA-617 (20 MBq), [¹⁷⁷Lu]Lu-PSMA-617 (20 MBq) and Trastuzumab (4 × 5 mg/kg), or left untreated. Tumor sizes and animal survival was observed. In vitro, x-ray irradiation did reduce survival in 22Rv1 but not PC-3 PIP cells, and there was no significant effect of Trastuzumab treatment. Cells expressed HER2 but not significantly elevated post irradiation. In vivo, mice co-treated with Trastuzumab had significantly longer survival than untreated mice, but not than only [¹⁷⁷Lu]Lu-PSMA-617. Staining of tumor sections showed similar HER2 and PSMA expression across groups. In conclusion, these results give no support for any benefit from co-treatment with anti-HER2 antibody for PSMA-targeted radioligand therapy.</p>","PeriodicalId":7572,"journal":{"name":"American journal of nuclear medicine and molecular imaging","volume":"13 3","pages":"107-117"},"PeriodicalIF":2.5,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10349288/pdf/ajnmmi0013-0107.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9823149","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of PSMA-based ¹⁸F-DCFPyL PET/CT and Tc-99m MDP bone scan in detection of bone metastasis in prostate cancer.","authors":"Zenus J Wilson,&nbsp;Guofan Xu,&nbsp;Sanjit O Tewari,&nbsp;Yang Lu","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>While Tc-99m MDP bone scan (BS) remains the conventional standard for detection of bone metastasis in prostate cancer, newly FDA-approved imaging with PSMA-based ¹⁸F-DCFPyL PET/CT has shown promise for early detection of metastatic disease. However, a paucity of data remains in the diagnostic accuracy of PSMA PET/CT in detecting bone metastasis compared to BS. This retrospective study included 91 patients who received both BS and PSMA PET/CT within a 3-month interval from August 2021 to February 2022. Separate concurrent primary cancer, interval PSA levels greater than a 2-fold difference (or absolute difference >1 ng/ml) between the two studies were excluded. All abnormal bone lesions on either scan were compared. The findings were verified by pathological findings and/or 6-month clinical follow-up. High concordance (78%) was found between modalities with discordant findings (20/91, 22%) demonstrating more false positives (4/20, 20%) and false negatives (3/20, 15%) on BS compared to PET/CT. Additionally, more bone metastases were detected on PSMA PET/CT (13/20, 65%) with all true positive BS lesions also detected PET/CT. The sensitivity, specificity, PPV and NPV for BS were 89%, 91%, 80%, and 95% respectively; and 100%, 97%, 93%, and 100% for ¹⁸F-DCFPyL PET/CT respectively. Our results demonstrate that ¹⁸F-DCFPyL PET/CT identified more bone metastases while also identifying all bone metastases identified on BS. With the added diagnostic value of detecting primary tumor and soft tissue metastasis, ¹⁸F-DCFPyL PET/CT may render BS unnecessary to investigate bone metastases in patients with prostate cancer.</p>","PeriodicalId":7572,"journal":{"name":"American journal of nuclear medicine and molecular imaging","volume":"13 1","pages":"1-10"},"PeriodicalIF":2.5,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10009469/pdf/ajnmmi0013-0001.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9122053","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Claudin18.2-targeted cancer theranostics.","authors":"Di Zhang,&nbsp;Gang Huang,&nbsp;Jianjun Liu,&nbsp;Weijun Wei","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Claudin 18.2 (CLDN18.2) is an emerging target for the treatment of CLDN18.2-expressing cancers such as gastric and pancreatic cancers. Cell and antibody therapies targeting CLDN18.2 are under intensive clinical trials. In this setting, how to efficiently and specifically detect CLDN18.2 expression before and after the therapies is a clinical challenge. In recent years, molecular imaging with radiolabeled antibodies or antibody fragments have shown promise in noninvasively annotating antigen expression across the body. In this <i>Perspective</i>, we will bring together the most recent progress on CLDN18.2-targeted imaging and therapy of solid tumors.</p>","PeriodicalId":7572,"journal":{"name":"American journal of nuclear medicine and molecular imaging","volume":"13 2","pages":"64-69"},"PeriodicalIF":2.5,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10193197/pdf/ajnmmi0013-0064.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9496438","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Uterine adenosarcoma: a case report and review of the literature.","authors":"Qiyue Wang,&nbsp;Si Sun,&nbsp;Jing Cai,&nbsp;Lu Yang,&nbsp;Gang Lv,&nbsp;Qiang Yang","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Uterine adenosarcoma is a rare gynecological malignancy with no specific symptoms, and the optimal management is still inconclusive. Herein we present a case of uterine adenosarcoma in a 38-year-old woman with a good prognosis and review of literatures. The patient presented with abnormal vaginal bleeding with no special medical history. Sonographic scan revealed a heterogeneous echoic mass in the cavity, indicating a polypus or a submucous myoma. The pathology based on the specimen after the hysteroscopic tumor excision suggested diagnosis of uterine adenosarcoma. Subsequently, the patient received pelvic MRI scan before surgery. MRI identified a patchy lesion at the cervix-lower endometrial cavity with low signal in T1WI and a mixed high T2 signal in T2WI, with no sign of metastasis. Then total abdominal hysterectomy with bilateral salpingo-oopherectomy plus pelvic lymph node dissection was performed and 6 cycles of chemotherapy were administered. The patient remains disease-free on follow-up to date, more than 15 months after chemotherapy.</p>","PeriodicalId":7572,"journal":{"name":"American journal of nuclear medicine and molecular imaging","volume":"13 2","pages":"70-76"},"PeriodicalIF":2.5,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10193199/pdf/ajnmmi0013-0070.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9874581","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessment of the correlation between arterial lumen density and its metabolic activity in atherosclerotic patients using ¹⁸F-FDG positron emission tomography/computed tomography.","authors":"Mamdouh S Al-Enezi","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Large lipid core (extended into arterial lumen) and high density of macrophages (associated with ¹⁸F-fluorodeoxyglucose \"¹⁸F-FDG\" uptake) in atherosclerotic plaque were shown to be an overt feature of plaque rupture. Nineteen participants were imaged with computed tomography (CT) and positron emission tomography (PET) with ¹⁸F-FDG in a dynamic mode. The mean lumen density in Hounsfield unit (HU) was measured per region of interest (ROI) on CT images and classified as non-calcified and calcified classifications. Calcified group was divided into partially calcified and calcified groups. Metabolic rate of glucose (MRG) was computed per ROI on PET dynamic images using modified 2-tissue compartmental model that is independent of partial volume effect. Data is clustered using Automatic Hierarchical K-means algorithm (AKH) with silhouette-coefficient. Arterial segments of 1180 ROIs for Aorta and iliac arteries were classified as non-calcified and calcified segments and clustered using AHK with respect to the mean of intravascular attenuation (in HU). There was a statistical difference in MRG corresponded to low intravascular attenuation cluster compared to higher intravascular attenuation clusters (P<0.05), but not within higher clusters (P>0.05), for both non-calcified and calcified classes. In partially calcified segments, same pattern was observed as the low intravascular attenuation cluster was accompanied with significant metabolic activity but not for calcified segments. Low intravascular attenuation is associated with high MRG measured on ¹⁸F-FDG PET images, which may reflect the instability of atherosclerotic plaque. Partially calcified plaque is metabolically active compared to calcified plaque.</p>","PeriodicalId":7572,"journal":{"name":"American journal of nuclear medicine and molecular imaging","volume":"13 1","pages":"18-25"},"PeriodicalIF":2.5,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10009471/pdf/ajnmmi0013-0018.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9122055","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erratum: Single-center developing country analysis of radium-223 therapy in prostate cancer-preliminary results.","authors":"Thaís B Minekawa,&nbsp;Allan O Santos,&nbsp;André G Moraes,&nbsp;André Sasse,&nbsp;Cleide A Silva,&nbsp;Marcelo T Lima,&nbsp;Mariana Camacho,&nbsp;Mariana C Lima,&nbsp;Elba Etchebehere","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>[This corrects the article on p. 352 in vol. 11, PMID: 34754606.].</p>","PeriodicalId":7572,"journal":{"name":"American journal of nuclear medicine and molecular imaging","volume":"13 3","pages":"126"},"PeriodicalIF":2.5,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10349289/pdf/ajnmmi0013-0126.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9816657","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PSMA-based ¹⁸F-DCFPyL PET: a better choice than multiparametric MRI for prostate cancer diagnosis?","authors":"Xiao Zhang, Mai Hong Son, Le Ngoc Ha, Xiaoli Lan","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Owing to the high tissue contrast, multiparametric MRI (mpMRI) has already been the most widely applied imaging method for prostate cancer. Recently, prostate-specific membrane antigen (PSMA) ligands for nuclear imaging are emerging as a promising modality in prostate cancer, especially since the 2 PET/CT agents (⁶⁸Ga-PSMA-11 and ¹⁸F-DCFPy) approved by U.S. Food and Drug Administration (FDA). However, limited studies have performed the comparison of mpMRI versus recently approved ¹⁸F-DCFPyL PET/CT. In this issue of AJNMMI, Lu et al. compared the performance of ¹⁸F-DCFPyL PET/CT and pelvic mpMRI in intermediate-high risk and biochemical recurrent prostate cancer patients. The results demonstrated the two modalities have a good concordance rate for patient-based analysis, and ¹⁸F-DCFPyL PET/CT has a better diagnostic performance in detecting lymph node metastases and bone metastases for lesion-based analysis. The use of ¹⁸F-DCFPyL PET/CT provides more diagnostic confidence to better assess prostate cancer lesions.</p>","PeriodicalId":7572,"journal":{"name":"American journal of nuclear medicine and molecular imaging","volume":"12 6","pages":"195-200"},"PeriodicalIF":2.0,"publicationDate":"2022-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9831858/pdf/ajnmmi0012-0195.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9091777","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic efficacy of SPECT/CT MPI and CMR in children with myocarditis caused by different infection sources.","authors":"Luxi Yang, Jicheng Li, Kai Zhang, Kexin Zhao, Yahong Liu, Yongjun Luo, Lele Huang, Xiaowei Zhang","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>This study aimed to analyze the diagnostic efficacy of ^99mTc-methoxy isobutyl isonitrile (MIBI) single photon emission tomography (SPECT/CT) myocardial perfusion imaging (MPI) and cardiac magnetic resonance imaging (CMR) in children with myocarditis caused by different infection sources and provide an imaging reference basis for clinical diagnosis and treatment. In total, 232 children diagnosed with myocarditis were retrospectively divided into five groups according to the different infection sources: viral infection (group A), bacterial infection (group B), viral combined with bacterial infection (group C), viral combined with mycoplasma infection (group D), and bacterial combined with mycoplasma infection (group E). A chi-square test and ANOVA were used to analyze the difference between SPECT/CT MPI and CMR in the diagnosis of myocarditis in children according to their categorical infection source group, including the impact of the average daily hospital costs (a=0.05). The positive rates of SPECT/CT in groups A and D were higher than those of CMR, and the positive rates of SPECT/CT in groups C and E were lower than those of CMR, with statistically significant differences (P < 0.05). The SPECT/CT ischemic lesions were located in the anterior wall, or the anterior wall combined with other walls of the left ventricle in 69.5% of patients. SPECT/CT MPI had no effect on the average daily hospitalization cost (P > 0.05); however, the average daily hospitalization cost of CMR-negative patients in group D was higher than that of CMR-positive patients, and it was statistically significant in groups C and E (P < 0.05). In groups A and D, the use of ^99mTc-MIBI SPECT/CT MPI was preferred for diagnosing myocarditis. The detection rate of CMR was higher in groups C and E. SPECT/CT MPI findings of ischemic segments were mostly found in the anterior wall. The results of CMR diagnosis affected the average daily hospitalization cost among patients with different infection sources; however, SPECT/CT had no such effect. These findings denote a potential targeted approach to myocarditis diagnosis in pediatric patients based on source of infection.</p>","PeriodicalId":7572,"journal":{"name":"American journal of nuclear medicine and molecular imaging","volume":"12 6","pages":"180-187"},"PeriodicalIF":2.0,"publicationDate":"2022-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9831860/pdf/ajnmmi0012-0180.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9076387","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A novel tetrapeptide for chelator-free radiolabeling in optimized preparation of ^99mTc-radiolabeled oligonucleotides.","authors":"Zhao Chen,&nbsp;Qi Yang,&nbsp;Lele Song,&nbsp;Yongkang Qiu,&nbsp;Sitong Wu,&nbsp;Wenpeng Huang,&nbsp;Qiao Jiang,&nbsp;Shengnan Wu,&nbsp;Lei Kang","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Antisense imaging uses radionuclide labeled antisense oligonucleotides to hybridize with nucleic acids in vivo, display the expression of target genes, and directly quantify biological processes at the cellular and subcellular levels. The anti-miRNA oligonucleotides (AMOs) are a series of single-stranded DNA oligonucleotides that are widely used in gene imaging and gene therapy. However, due to the negative charge and high molecular weight, the permeability through the membrane of AMOs is generally low so that most AMOs cannot enter the cells. Based on the ^99mTc-labeled AMOs imaging in previous studies, this study developed a novel tetrapeptide Glycine-Alanine-Glycine-Lysine (Gly-Ala-Gly-Lys, GAGK) for one-step labeling AMO with ^99mTc. The labeling conditions were optimized by changing the number of stannous ions, the reaction time, and the temperature, respectively. The labeled products were identified by gel electrophoresis and their serum stability was evaluated. The optimal labeling condition in this study was using 1 mg/mL SnCl₂·2H₂O and heating for 30 min at 100°C. Gel electrophoresis confirmed the verification of successful labeling of ^99mTc-GAGK-AMO. After being incubated with human fresh serum for 12 h, ^99mTc-GAGK-AMO showed good stability and no obvious degradation. Therefore, this labeling method has high labeling efficiency and stable labeling, which provides an effective method for the application of miRNA-targeted imaging.</p>","PeriodicalId":7572,"journal":{"name":"American journal of nuclear medicine and molecular imaging","volume":"12 5","pages":"143-151"},"PeriodicalIF":2.5,"publicationDate":"2022-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9677136/pdf/ajnmmi0012-0143.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40721585","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}